The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST.
Venkatesh Pilla ReddyRana AnjumMichael GrondineAaron SmithDeepa BhavsarEvan BarrySylvie M GuichardWenlin ShaoJason G KettleCrystal BrownErica BanksRhys D O JonesPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
We demonstrate that AZD3229 warrants clinical investigation as a new treatment for patients with GIST based on its ability to inhibit both ATP-binding and A-loop mutations of KIT at clinically relevant exposures.
Keyphrases